In This Article:
As the U.S. stock market experiences a downturn, particularly impacting major tech companies, investors are reassessing their strategies amid fluctuating earnings reports and economic indicators. In this climate of uncertainty, penny stocks—though often overlooked—continue to present intriguing opportunities for growth, especially when they boast solid financial health. These smaller or newer companies can offer unique value and growth prospects that larger firms might miss, making them an appealing option for those looking to uncover potential in under-the-radar investments.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.799 | $5.75M | ★★★★★★ |
| LexinFintech Holdings (NasdaqGS:LX) | $3.19 | $534.34M | ★★★★★★ |
| RLX Technology (NYSE:RLX) | $1.63 | $2.12B | ★★★★★★ |
| Permianville Royalty Trust (NYSE:PVL) | $1.575 | $50.82M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $69.71M | ★★★★★★ |
| MIND C.T.I (NasdaqGM:MNDO) | $1.88 | $39.56M | ★★★★★★ |
| ARC Document Solutions (NYSE:ARC) | $3.41 | $147.91M | ★★★★★★ |
| Commercial Vehicle Group (NasdaqGS:CVGI) | $3.01 | $99.68M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $1.10 | $98.93M | ★★★★★☆ |
| So-Young International (NasdaqGM:SY) | $1.25 | $97.93M | ★★★★☆☆ |
Click here to see the full list of 756 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
HeartBeam
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: HeartBeam, Inc. is a medical technology company that develops and commercializes ambulatory electrocardiogram solutions for detecting and monitoring cardiac disease both inside and outside healthcare facilities, with a market cap of $64.01 million.
Operations: HeartBeam, Inc. does not currently report any revenue segments.
Market Cap: $64.01M
HeartBeam, Inc., a medical technology company with a market cap of US$64.01 million, remains pre-revenue and unprofitable. Despite having no debt or long-term liabilities and short-term assets exceeding liabilities, the company faces financial challenges with less than a year of cash runway. Recent executive changes include Robert Eno as CEO to lead efforts for FDA 510(k) clearance and commercialization of their vector-based ECG technology. HeartBeam's innovative approach is supported by 13 U.S. patents but requires significant progress towards revenue generation to improve its financial position in the penny stock market segment.
-
Click to explore a detailed breakdown of our findings in HeartBeam's financial health report.
-
Gain insights into HeartBeam's future direction by reviewing our growth report.
NeoVolta
Simply Wall St Financial Health Rating: ★★★★☆☆